PRINCETON, N.J.–(BUSINESS WIRE)–Oyster Point Pharma, Inc., a privately held clinical-stage
pharmaceutical company with an initial focus on developing novel
therapies for the treatment of Dry Eye Disease, today announced that
Jeffrey Nau, Ph.D., M.M.S, President and CEO, is scheduled to present a
corporate overview at the 8th Annual SVB Leerink Global Healthcare
Conference on Wednesday, February 27th, 2019 at 1:30pm EST in New York.
About Oyster Point Pharma, Inc.
Oyster Point Pharma is a clinical-stage pharmaceutical company
leveraging neuroscience to discover, develop, and commercialize novel
therapies to treat diseases with high unmet needs. The company’s initial
focus is to develop innovative therapeutics to treat the signs and
symptoms of Dry Eye Disease by stimulating the trigeminal
parasympathetic pathway to activate the glands and cells responsible for
tear film production, known as the Lacrimal Functional Unit. Oyster
Point is leveraging a class of molecules called nicotinic acetylcholine
receptor (nAChR) agonists to bind receptors on the trigeminal nerve,
accessible within the nose, to stimulate natural tear film production.
For more information visit oysterpointrx.com
and follow on Twitter at @OysterPointRx.
Contacts
Krysta Pellegrino
650-255-6142
Krysta@healthandcommerce.com
LOS ANGELES--(BUSINESS WIRE)--Molasses Manifesto has set its latest feature film, THE FAR WAY, a character-driven…
Analog Way is pleased to announce CorePlay 1.4, a new software update for its CorePlay…
LEXINGTON, KY / ACCESS Newswire / April 9, 2026 / Cardiff Lexington Corporation (OTCQX:CDIX) ("Cardiff…
"Designing for Dignity: Reshaping Perceptions of Mobility" reveals how design-forward innovation is shifting mobility from…
Collaboration leverages Imagene's OI Suite, powered by CanvOI and a large-scale multimodal real-world data lake,…
This purchase of improved forest management credits reflects a growing shift toward a higher-quality carbon…
